S&P Futures
3,938.50 -8.50 (-0.22%) Dow Futures
31,960.00 -111.00 (-0.35%) Nasdaq Futures
12,648.25 +3.50 (+0.03%) Russell 2000 Futures
1,734.40 -4.00 (-0.23%) Crude Oil
65.35 -1.39 (-2.08%) Gold
1,995.40 +21.90 (+1.11%)
Heron Therapeutics, Inc. (HRTX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 2.3900 |
| Open | 2.3700 |
| Bid | 2.0300 x 900 |
| Ask | 2.4600 x 1800 |
| Day's Range | 2.1500 - 2.3700 |
| 52 Week Range | 2.0800 - 6.3800 |
| Volume | |
| Avg. Volume | 1,730,425 |
| Market Cap | 284.142M |
| Beta (5Y Monthly) | 0.86 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.1200 |
| Earnings Date | Mar 23, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.42 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for HRTX
Related Research
- Heron Therapeutics, Inc.Market Digest: LVS, MRK, NSC, GNRC, DOCUStocks held up on March 13 after some ugly early action that saw the S&P 500 (SPX) down about 1.3%. The index rallied almost 100 points by late morning before selling off over the balance of the day. It was a great session for day traders, but created more agita for the rest of us. The morning low coincided with chart support in the 3,780-3,810 region from the late-December low. On March 14, gains were solid and broad-based.RatingFair ValueEconomic Moat5 days agoArgus Research
- PR Newswire
Heron Therapeutics Announces Centers for Medicare & Medicaid Services (CMS) Granted Pass-through Payment Status for APONVIE™, Effective April 1, 2023
Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that CMS has approved transitional pass-through status for APONVIE (aprepitant) injectable emulsion, which will be established for three years beginning April 1, 2023 under C-code C9145. APONVIE was approved by the U.S. Food and Drug Administration (FDA) for in
- PR Newswire
Heron Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 23, 2023
Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the company will host a conference call and live webcast on Thursday, March 23, 2023 at 4:30 p.m. ET to report fourth quarter and full year 2022 financial results and discuss recent business highlights.
- PR Newswire
Heron Therapeutics Announces U.S. Commercial Launch of APONVIE™ for the Management of Postoperative Nausea and Vomiting in Adults
Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced APONVIE (aprepitant) injectable emulsion, is now commercially available for intravenous (IV) use in adults for the prevention of PONV.
